Levistolide A
Based on 5 publication(s) in Google Scholar
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.34%
- CAS No.: 88182-33-6
- 화학식: C24H28O4
- 분자량:380.48
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Levistolide A
More
Biological Activity
Levistolide A (50, 100 μM; 24 h) induces apoptosis in colon cancer cells by promoting ROS generation and mediating the endoplasmic reticulum stress pathway[1]. Levistolide A (1.1, 3.3, 10 μg/mL) activates peroxisome proliferator activated receptor gamma (PPARγ) in N2a/APP695swe cells and reduces tau hyperphosphorylation through the GSK3 α/β pathway, thereby reducing the production and aggregation of β - amyloid protein (A β)[2]. Levistolide A (20-80 μM; 36 h) can inhibit the replication of Porcine Epidemic Diarrhea Virus (PEDV) by inducing ROS generation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 human colon cancer cells
-
Concentration:50, 100 μM
-
Incubation Time:24 h
-
Result:Promoted cell apoptosis in a dose-dependent manner.
-
Cell Line:N2a/APP695swe cells
-
Concentration:1.1, 3.3, 10 μg/mL
-
Incubation Time:
-
Result:Promoted the protein expression of PPAR γ in cells.
-
Cell Line:Vero cells
-
Concentration:20-80 μM
-
Incubation Time:36 h
-
Result:Inhibited the generation of PEDV RNA.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Amyloid precursor protein/presenilin 1 (APP/PS1) transgenic (Tg) mouse model[2].
-
Dosage:2 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once every two days
-
Result:Improved memory impairment and cognitive decline in APP/PS1 Tg mice, and reduced the generation of A β and inflammatory response in the mouse brain.
-
Animal Model:5/6 nephrectomy (Nx) mice [4].
-
Dosage:0.5-2 mg/kg
-
Administration:Intraperitoneal injection (i.p.); once every two days; 4 weeks
-
Result:Inhibited expression levels of renin and Ang II, inflammation and oxidative stress and improved renal fibrosis.
Chemical Information
-
CAS No. 88182-33-6
-
Appearance Solid
-
분자량 380.48
-
화학식 C24H28O4
-
Color White to off-white
-
SMILES
O=C(O/C([C@@]1(CC2)[C@]34[H])=C\CCC)C1=C[C@]2([H])[C@]3([H])CCC5=C4C(O/C5=C\CCC)=O
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
-
Bioorg Chem
Exploring the mechanism of Levistolide A in the treatment of lung cancer cells based on network analysis, molecular docking and experimental validation. [Abstract]2025 Sep 16:165:109002. PMID: 40974659 -
Viruses
2022 Jan 27;14(2):258. PMID: 35215851 -
Curr Issues Mol Biol
Levistolide A Alleviates Myocardial Ischemia-Reperfusion Injury Partly by Improving Calcium Homeostasis via the ADORA2B/cAMP/PKA/PLB/SERCA2α Signaling Axis. [Abstract]2026 Jan 23;48(2):125. PMID: 41751389
용액&용해도
DMSO : 100 mg/mL (262.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.57 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC/saline water
Solubility: 3.33 mg/mL (8.75 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (286 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yang Y, et al. Levistolide A Induces Apoptosis via ROS-Mediated ER Stress Pathway in Colon Cancer Cells. Cell Physiol Biochem. 2017;42(3):929-938. [Content Brief]
[2]. Qu X, et al. Levistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway. Neurotherapeutics. 2021 Jan;18(1):326-339. [Content Brief]
[3]. Zeng W, et al. Levistolide A Inhibits PEDV Replication via Inducing ROS Generation. Viruses. 2022 Jan 27;14(2):258. [Content Brief]
[4]. Aobulikasimu N, et al. Levistolide A ameliorates fibrosis in chronic kidney disease via modulating multitarget actions in vitro and in vivo. Life Sci. 2023 May 1;320:121565. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | 65.7065 mL |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | 13.1413 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL | 6.5706 mL | |
| 15 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | 4.3804 mL | |
| 20 mM | 0.1314 mL | 0.6571 mL | 1.3141 mL | 3.2853 mL | |
| 25 mM | 0.1051 mL | 0.5257 mL | 1.0513 mL | 2.6283 mL | |
| 30 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 40 mM | 0.0657 mL | 0.3285 mL | 0.6571 mL | 1.6427 mL | |
| 50 mM | 0.0526 mL | 0.2628 mL | 0.5257 mL | 1.3141 mL | |
| 60 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0951 mL | |
| 80 mM | 0.0329 mL | 0.1643 mL | 0.3285 mL | 0.8213 mL | |
| 100 mM | 0.0263 mL | 0.1314 mL | 0.2628 mL | 0.6571 mL |